Abstract
Asthma is characterized by chronic inflammation and reversibility of the airways. The disease is characterized
by inflammation of eosinophils.
Recently, a new disease related to innate immunity has been proposed, and it has been found that there are
several subtypes of refractory asthma. Biomarkers are also being explored to identify therapeutic targets during
diagnosis. New treatments for asthma include an increase in inhaled drug types and antibody therapy with biologics targeting refractory asthma. In addition, we can choose to treat asthma by respiratory intervention using bronchoscopy.
Asthma treatment, like that of other diseases, benefits from personalization.
